Drug Trial Radar · NCT06380660
Study of ACE-86225106 to Treat Patients With Advanced Solid Tumors
Last checked: Nov 20, 2026Latest source record: Aug 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
298
Planned (sponsor's estimate)
Start
Mar 22, 2024
Primary completion
Dec 21, 2028
Study completion Mar 21, 2029
Sponsor
- Lead sponsor
- Acerand Therapeutics (Shanghai) LimitedIndustry
- Sponsor type
- Industry
- First posted
- Apr 24, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine if the experimental treatment with poly-ADP ribose polymerase (PARP) inhibitor, ACE-86225106 is safe, tolerable and has anti-cancer activity in adult patients with advanced solid tumors.
Conditions
- Solid Tumor, Adult
- BRCA1 Mutation
- BRCA2 Mutation
- Ovarian Cancer
- Breast Cancer
- Prostate Cancer
Interventions
ACE-86225106 tabletDrug
ACE-86225106 will be administered orally daily as a continuous regimen. Subjects will continue to receive study treatment until PD as judged by local investigator review, development of unacceptable toxicity, or withdrawal of consent.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants experiencing adverse events (AEs)/serious adverse events (SAEs)Time frame: From time of information consent to 30 days post last dose, up to 3 years
- The number of patients experiencing dose limiting toxicity (DLT), as defined in the protocolTime frame: From the first dose of ACE-86225106 on Cycle 1 Day 1 up to and including the planned end of Cycle 1 (at the end of 28 days)
- Recommended Phase 2 dose (RP2D) and/or maximum tolerated dose (MTD)Time frame: Up to 3 years
Locations
14 sites in 1 country. Site status is shown where the registry gives one.
Chongqing Cancer Hospital
Chongqing, Chongqing Municipality, China
Fujian Cancer Hospital
Fuzhou, Fujian, China
Sun Yat-Sen University Cancer Center
Guangzhou, Guangdong, China
Anyang Cancer Hospital
Anyang, Henan, China
Henan Cancer Hospital
Zhengzhou, Henan, China
Hubei Cancer Hospital
Wuhan, Hubei, China
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China
Hunan Cancer Hospital
Changsha, Hunan, China
Jinan Central Hospital
Jinan, Shandong, China
Qilu Hospital Shangdong University
Jinan, Shandong, China
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China
Second Hospital Affiliated to Shanxi Medical University
Taiyuan, Shanxi, China
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China
First Hospital Affiliated to Wenzhou Medical University
Wenzhou, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.